Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
PBYI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.23 - $6.06
Previous CloseN/A
Volume522.58K
Average Volume (3M)460.04K
Market Cap
$143.87M
Enterprise Value$123.81M
Total Cash (Recent Filing)$41.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)4.8
Beta0.78
Next Earnings
May 01, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding49,610,798
10 Day Avg. Volume299,787
30 Day Avg. Volume460,035
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)N/A
Price to Sales (P/S)0.76
Price to Cash Flow (P/CF)2.80
P/FCF Ratio2.80
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.75
Enterprise Value/Ebitda2.58
Forecast
1Y Price Target
$4.33Price Target Upside49.31% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Puma Biotechnology News
PremiumCompany Announcements
Puma Biotechnology’s Earnings Call: Mixed Sentiments and Future Outlook
PremiumCompany Announcements
Puma Biotechnology Reports Strong Earnings Growth in 2024
---
Bulls Say, Bears Say
Bulls Say
EarningsNerlynx net sales beat guidance and our estimate in 4Q24.
Market ExpansionThe inclusion of Nerlynx in the updated NCCN Guidelines for Cervical Cancer as a treatment option signifies a potential increase in demand for the drug.
Bears Say
Demand DeclineNerlynx demand/volumes continue to decline, management has largely been able to counteract this with price increases.
Prescription TrendsNew prescriptions in 4Q24 decreased approximately 7% QoQ.
---
Ownership Overview
31.95% Insiders
12.43% Mutual Funds
12.94% Other Institutional Investors
32.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PBYI FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was $2.23 and its highest was $6.05 in the past 12 months.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market cap is $143.87M.
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is May 01, 2025 which is in 23 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Feb 27, 2025. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.087 by $0.303.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Undervalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is -0.02.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 49,610,798 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of $0.39 in its last earnings report, beating expectations of $0.087. Following the earnings report the stock price went up 19.732%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Currently, no hedge funds are holding shares in PBYI
---
Puma Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.33 (49.31% Upside)
$4.33 (49.31% Upside)
Blogger Sentiment
Bullish
PBYI Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 9.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-47.36%
12-Months-Change
Fundamentals
Return on Equity
41.60%
Trailing 12-Months
Asset Growth
-6.85%
Trailing 12-Months
Company Description
Puma Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
---
PBYI Company Deck
---
PBYI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive advancements in clinical trials and regulatory approvals, as well as ongoing challenges with revenue and prescription declines. While the company continues to maintain a positive net income, the drop in royalty revenue and NERLYNX net product revenue raises concerns.Read More>---
PBYI Stock 12 Month Forecast
Average Price Target
$4.33
▲(49.31% Upside)
Technical Analysis
Best Analysts Covering PBYI
1 Year
1 Year Success Rate
18/28 ratings generated profit
1 Year Average Return
+6.17%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +6.17% per trade.
---